MedPath

Treatment of Hyperglycaemia and Insulin Resistance in HIV Infected Patients

Not Applicable
Completed
Conditions
Insulin Resistance
Registration Number
NCT00483392
Lead Sponsor
University Medical Centre Ljubljana
Brief Summary

The purpose of this study is to evaluate and compare the effects of treatment with rosiglitazone and metformin on insulin resistance in patients infected with Human Immunodeficiency Virus on stable Highly Active Antiretroviral Therapy including a Protease Inhibitor after the period of 48 weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
Not specified
Inclusion Criteria
  • documented HIV infection
  • stable Protease Inhibitor containing HAART regimen for at least 12 months
  • impaired glucose tolerance
  • elevated insulin levels (above 20 mIU/l)
Exclusion Criteria
  • patients already taking oral hypoglycaemic treatment or insulin
  • heart failure NYHA I-IV
  • liver disease or kidney disease
  • elevated AST or ALT above 2 times upper normal range
  • elevated creatinine (above 150 mmol/l)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
fasting plasma glucose, basal insulin levels48 weeks
Secondary Outcome Measures
NameTimeMethod
insulin resistance, beta cell function48 week

Trial Locations

Locations (1)

Department of Endocrinology, Diabetes and Metabolic diseases

🇸🇮

Ljubljana, Slovenia

© Copyright 2025. All Rights Reserved by MedPath